Previous 10 | Next 10 |
DEER PARK, Ill., May 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the first quarter ended March 31, 2020 and provided an upda...
-Eton confirms first-to-file ANDA referencing Exela Pharma Sciences’ Elcys product -Eton plans to file Post Grant Reviews in the U.S. Patent & Trademark Office challenging the validity of Exela’s listed patents, which, if successful, could allow Eton to launch in 2021 ...
DEER PARK, Ill., May 06, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report first quarter 2020 financial and operating results on Thursd...
DEER PARK, Ill., May 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it has appointed Paul Stickler as the company’s new Senior Vice Pres...
Gainers: Top Ships (NASDAQ: TOPS ) +115% . More news on: Top Ships Inc., THL Credit, Bio-Path Holdings, Inc., Stocks on the move, , Read more ...
Eton Pharmaceuticals (NASDAQ: ETON ) has acquired U.S. rights to Diurnal Group plc's Alkindi Sprinkle as a replacement therapy for pediatric adrenal insufficiency, including congenital adrenal hyperplasia, in young patients up to the age of 17, an Orphan Drug-tagged indication. More news...
-Estimated Market Opportunity of Greater than $100 Million -Alkindi Sprinkle NDA has been Assigned a September 29, 2020 Prescription Drug User Fee Act Date -Alkindi Sprinkle has been Granted Orphan Drug Designation for Adrenal Insufficiency in Pediatric Patients -Eton Executed $7.8 M...
Thinly traded nano cap Eton Pharmaceuticals ( ETON +6.1% ) is up, albeit on turnover of only 46K shares, on the heels of positive results from a bioequivalence study of ET-101, an oral solution formulation of anti-seizure and anti-migraine med topiramate. More news on: Eton Pharmaceuti...
-Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation -Market for Topiramate in Oral Form is Greater than $800 million Annually DEER PARK, Ill., March 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical compa...
Assuming no COVID-19 cancellations, here is a list of noteworthy events during the week of March 15 - 21 for healthcare investors: More news on: Eton Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Arcutis Biotherapeutics, Inc., Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...